EUCTR2010-022181-28-PL进行中（未招募）不适用
A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophrenia
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- The patient meets the DSM-IV-TR criteria for schizophrenia (codes 295.10, 295.20, 295.30, 295.90)
- •- The patient is a man or woman, =18 and =65 years old
- •- The patient has a PANSS total score =60 and =100 at screening and baseline
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- The patient has a current Axis I psychiatric disorder other than schizophrenia as defined in the DSM-IV-TR
- •- The patient has a current diagnosis or a history of substance dependence (except nicotine) or substance abuse (except cannabis) according to the DSM-IV-TR? criteria =6 months prior to screening
- •- The patient is at significant risk of harming himself/herself or others according to the investigator’s judgement (assisted by the assessment of suicidal ideation and behaviour using the C-SSRS)
- •- The patient is resistant to antipsychotic treatment according to the investigator’s judgement or has been treated with clozapine = 3 months prior to screening
- •- The patient has experienced an acute exacerbation requiring hospitalisation = 3 months prior to screening or between screening and baseline
- •- The patient has been treated with risperidone or paliperidone =6 months prior to screening
- •- The patient has been treated with an adequate course of risperidone or paliperidone and failed to respond or has shown intolerance to the drug according to the investigator`s judgement
研究者
相似试验
进行中（未招募）
不适用
A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophreniaSchizophreniaEUCTR2010-022181-28-CZH. Lundbeck A/S160
进行中（未招募）
不适用
The study is measuring the safety and effect of the study drug zicronapine in the treatment of patients with schizophrenia. Patients will receive either the study drug (zicronapine) or risperidone based on a computer-aided random draw, and no one involved in the study will know what treatment is given until the study has finished.SchizophreniaEUCTR2010-022181-28-FIH. Lundbeck A/S160
进行中（未招募）
不适用
The study is measuring the safety and effect of the study drug zicronapine in the treatment of patients with schizophrenia. Patients will receive either the study drug (zicronapine) or risperidone based on a computer-aided random draw, and no one involved in the study will know what treatment is given until the study has finished.SchizophreniaEUCTR2010-022181-28-EEH. Lundbeck A/S160
进行中（未招募）
不适用
A six-week, randomized, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of the combination of aliskiren 150 mg and amlodipine 5 mg compared to amlodipine 5 mg and 10 mg in hypertensive patients not adequately responsive to amlodipine 5 mgHypertensionEUCTR2004-002410-11-DKovartis Pharma Services AG504
进行中（未招募）
不适用
A six-week, randomized, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of the combination of aliskiren 150 mg and amlodipine 5 mg compared to amlodipine 5 mg and 10 mg in hypertensive patients not adequately responsive to amlodipine 5 mgHypertensionEUCTR2004-002410-11-DEovartis Pharma Services AG566